Analysts Set GeoVax Labs, Inc. (NASDAQ:GOVX) PT at $14.20

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been given an average rating of “Buy” by the seven analysts that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $14.20.

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research report on Friday, November 15th. D. Boral Capital reissued a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a report on Tuesday, November 19th. Noble Financial increased their price objective on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. Finally, Alliance Global Partners initiated coverage on shares of GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price target on the stock.

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC bought a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission (SEC). 6.09% of the stock is owned by institutional investors.

GeoVax Labs Trading Down 1.6 %

Shares of NASDAQ:GOVX opened at $2.40 on Friday. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18. The company’s fifty day moving average price is $2.33 and its 200 day moving average price is $2.73.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same period in the previous year, the business posted ($4.80) earnings per share. On average, analysts anticipate that GeoVax Labs will post -4.49 EPS for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.